New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed over ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluated epcoritamab as a monotherapy against R-GemOx Danish biotechnology company Genmab has announced top line ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are so lucky in DLBCL to make more rapid ...

Please provide your email address to receive an email when new articles are posted on . The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with ...

Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...

The 3-year event-free survival was 100% when ibrutinib (Imbruvica) was added to standard treatment for two genetic subtypes of diffuse large B-cell lymphoma (DLBCL) among patients age 60 years or ...

Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of single-agent epcoritamab (Epkinly) in the treatment of relapsed/refractory diffuse large B-cell lymphoma ...

For many patients diagnosed with diffuse large B-cell lymphoma (DLBCL), the first step in treatment is a standard regimen of chemotherapy. This approach cures most patients, but research shows that ...

Pivotal studies testing new options in previously untreated double-expressor (MYC/BCL2) diffuse large B-cell lymphoma (DLBCL) yielded differing results, according to findings presented at the recent ...